BridgeBio Touts Attruby Uptake, Bayer's Europe Rollout, and Pipeline Timelines

Company highlights accelerating U.S. patient adds, international expansion, and upcoming milestones at Leerink conference.

Mar. 13, 2026 at 1:49am

Got story updates? Submit your updates here. ›

BridgeBio Pharma (NASDAQ:BBIO) provided an update on the commercialization of its transthyretin (TTR) stabilizer Attruby, including accelerating U.S. patient adds and Bayer's progress with the European launch. The company also discussed timelines for its pipeline programs, including its in-house TTR 'depleter' and the upcoming NDA filing for its achondroplasia therapy infigratinib.

Why it matters

BridgeBio's ability to drive adoption of Attruby and advance its pipeline is crucial for the company's long-term growth. The update provides insights into the commercial dynamics of the TTR market and BridgeBio's strategy to establish Attruby as a foundational therapy, while also highlighting the potential of its other programs like the novel depleter approach and the oral achondroplasia treatment.

The details

BridgeBio reported that Attruby's weekly patient adds have increased from around 60 per week to more than 150, driven by factors like the drug's clinical profile, disease awareness efforts, and expansion beyond academic centers. The company also discussed Bayer's European rollout, noting strong initial uptake in Germany. On the pipeline front, BridgeBio plans to file a U.S. NDA for its achondroplasia therapy infigratinib in the second half of 2026, targeting a potential first-half 2027 launch. The company is also advancing an in-house TTR 'depleter' program, expected to enter the clinic in late 2027 or early 2028.

  • BridgeBio expects to file a U.S. NDA for infigratinib in achondroplasia in the second half of 2026.
  • BridgeBio's in-house TTR 'depleter' program is expected to enter the clinic in late 2027 or early 2028.

The players

BridgeBio Pharma

A clinical-stage biopharmaceutical company dedicated to discovering, developing, and delivering transformative medicines for patients with genetic diseases and cancers.

Bayer

BridgeBio's partner for the commercialization of acoramidis (marketed as Beyonttra) in Europe.

Chinmay Shukla

The SVP of Strategic Finance at BridgeBio Pharma.

Got photos? Submit your photos here. ›

What they’re saying

“Attruby's weekly patient adds have increased meaningfully since launch, rising from about 60 patients per week at an update roughly a year ago to 'more than 150 patients a week' as of the company's most recent update.”

— Chinmay Shukla, SVP of Strategic Finance (MarketBeat)

“Bayer has reported 'north of 50% treatment-naive share' in Germany, which he contrasted with the U.S. environment, citing Germany's single-payer system and fewer access hurdles.”

— Chinmay Shukla, SVP of Strategic Finance (MarketBeat)

What’s next

BridgeBio expects to file a U.S. NDA for its achondroplasia therapy infigratinib in the second half of 2026, potentially leading to a launch in the first half of 2027.

The takeaway

BridgeBio's update highlights the company's progress in driving adoption of its lead product Attruby, expanding its presence in Europe through its partnership with Bayer, and advancing its pipeline, including a novel TTR 'depleter' approach and an oral therapy for achondroplasia. These developments position BridgeBio for continued growth and reinforce its strategy of developing transformative medicines for patients with genetic diseases.